{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:36:40Z","timestamp":1769596600693,"version":"3.49.0"},"reference-count":45,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Immune thrombocytopenia (ITP) is a disease with variable clinical presentation, requiring different treatment lines.<\/jats:p><jats:p>\n          Aim\u2003The study aimed to characterize a group of ITP patients in terms of clinical picture and disease treatment, as well as to present the current standard of care of ITP in Poland, in the context of local and international guidelines.<\/jats:p><jats:p>\n          Materials and Methods\u2003The study included adult patients diagnosed with ITP, treated at the Department of Haematology of the Jagiellonian University Hospital in Krakow from January 2006 to January 2021. Patient characteristics, clinical manifestation of ITP, and treatment methods were analyzed.<\/jats:p><jats:p>\n          Results\u2003A total of 245 ITP patients were included. 57.1% of them were asymptomatic at diagnosis. Most common symptoms were thrombocytopenic purpura (68.2%), followed by epistaxis (34.7%) and gum bleeds (19.2%). Life-threatening bleedings were noted in three cases (1.2%). 23.2% of patients did not require treatment. Prednisone was the most commonly used first-line therapy (75.5% of patients). Treatment with eltrombopag and romiplostim was used in 40.4 and 8.5% of patients requiring second-line therapy, respectively. 14.3% of all patients ultimately underwent splenectomy, including 51.5% of those who needed second-line treatment. The initial response rate was 74.3%; however, post-splenectomy relapses occurred in 22.9% of patients.<\/jats:p><jats:p>\n          Conclusions\u2003ITP is a disease of mild clinical course, often asymptomatic. Chronic disease often requires multiple treatment lines and balancing between bleeding risk and treatment toxicity, based on individual risk\u2013benefit assessment. Local access restrictions to thrombopoietin receptor agonists determined the treatment strategy.<\/jats:p>","DOI":"10.1055\/a-1767-0304","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T23:35:33Z","timestamp":1654212933000},"page":"132-141","source":"Crossref","is-referenced-by-count":3,"title":["Immune Thrombocytopenia: Characteristics of the Population and Treatment Methods\u2014One-Center Experience"],"prefix":"10.1055","volume":"43","author":[{"given":"Weronika","family":"Lebowa","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital, Jagiellonian University Medical College, Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Zdziarska","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital, Jagiellonian University Medical College, Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospital, Jagiellonian University Medical College, Cracow, Poland"},{"name":"Department of Haematology, Jagiellonian University Medical College, Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/asheducation-2013.1.276","article-title":"Current management of immune thrombocytopenia","volume":"2013","author":"C E Neunert","year":"2013","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"26","key":"ref2","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"D B Cines","year":"2009","journal-title":"Blood"},{"key":"ref3","first-page":"1","article-title":"Wyst\u0119powanie i leczenie samoistnej plamicy ma\u0142op\u0142ytkowej (IPM) w Polsce na podstawie danych ankietowych PLATE. [Prevalence and treatment of immunethrombocytopenia in Poland, based on the PLATE questionnaire]","volume":"40","author":"K Zawilska","year":"2009","journal-title":"Acta Haematol Pol"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00277-016-2703-1","article-title":"Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis","volume":"95","author":"E Khodadi","year":"2016","journal-title":"Ann Hematol"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"B Olsson","year":"2003","journal-title":"Nat Med"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"M Chang","year":"2003","journal-title":"Blood"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"F Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"C Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref9","first-page":"2","article-title":"Polskie zalecenia post\u0119powania w pierwotnej ma\u0142op\u0142ytkowo\u015bci immunologicznej, opracowane przez Grup\u0119 ds. HemostazyPolskiegoTowarzystwaTransfuzjolog\u00f3w i Hematolog\u00f3w [Management of immune thrombocytopenia \u2013 guidelines of the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine]","volume":"120","author":"K Zawilska","year":"2010","journal-title":"Pol Arch Med Wewn"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1111\/trf.14915","article-title":"Incidence of immune thrombocytopenia in Taiwan: a nationwide population-based study","volume":"58","author":"G Y Hung","year":"2018","journal-title":"Transfusion"},{"issue":"22","key":"ref11","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"G Moulis","year":"2014","journal-title":"Blood"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3349\/ymj.2016.57.1.127","article-title":"High remission rate of chronic immune thrombocytopenia in children: result of 20-year follow-up","volume":"57","author":"C Y Kim","year":"2016","journal-title":"Yonsei Med J"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.14515","article-title":"State of the art - how I manage immune thrombocytopenia","volume":"177","author":"N Cooper","year":"2017","journal-title":"Br J Haematol"},{"issue":"23","key":"ref14","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"C Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"M P Lambert","year":"2017","journal-title":"Blood"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0039-1683416","article-title":"Epidemiology and clinical manifestations of immune thrombocytopenia","volume":"39","author":"R Kohli","year":"2019","journal-title":"Hamostaseologie"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.mayocp.2019.05.024","article-title":"Sequence of splenectomy and rituximab for the treatment of steroid-refractory immune thrombocytopenia: Does it matter?","volume":"94","author":"W A Hammond","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1538-7836.2009.03359.x","article-title":"Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial","volume":"7","author":"W Praituan","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"E499","DOI":"10.1002\/ajh.24529","article-title":"Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: a study of 27 cases","volume":"91","author":"S Melboucy-Belkhir","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3324\/haematol.2011.050799","article-title":"Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group","volume":"96","author":"T K\u00fchne","year":"2011","journal-title":"Haematologica"},{"issue":"16","key":"ref21","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"C Neunert","year":"2011","journal-title":"Blood"},{"issue":"22","key":"ref22","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"D Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"02","key":"ref23","first-page":"73","article-title":"Pharmacological treatment of primary immune thrombocytopenia in adults","volume":"11","author":"K Chojnowski","year":"2020","journal-title":"Hematologia"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone","volume":"349","author":"Y Cheng","year":"2003","journal-title":"N Engl J Med"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience","volume":"109","author":"M G Mazzucconi","year":"2007","journal-title":"Blood"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Y Wei","year":"2016","journal-title":"Blood"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"D Provan","year":"2010","journal-title":"Blood"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/ejh.13144","article-title":"Immune thrombocytopenia: effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment","volume":"101","author":"H Chang","year":"2018","journal-title":"Eur J Haematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"D J Kuter","year":"2008","journal-title":"Lancet"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"M N Saleh","year":"2013","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"G Cheng","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ajh.23299","article-title":"Platelet count or bleeding as the outcome in ITP trials?","volume":"87","author":"D M Arnold","year":"2012","journal-title":"Am J Hematol"},{"issue":"22","key":"ref33","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"M Khellaf","year":"2014","journal-title":"Blood"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"B Godeau","year":"2008","journal-title":"Blood"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens","volume":"84","author":"A Hasan","year":"2009","journal-title":"Am J Hematol"},{"issue":"03","key":"ref36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.2008.01100.x","article-title":"Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results","volume":"81","author":"M Medeot","year":"2008","journal-title":"Eur J Haematol"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"E267","DOI":"10.1002\/ajh.24310","article-title":"Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years","volume":"91","author":"F Palandri","year":"2016","journal-title":"Am J Hematol"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"S Chaturvedi","year":"2018","journal-title":"Blood"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00277-002-0461-8","article-title":"Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses","volume":"81","author":"S Kumar","year":"2002","journal-title":"Ann Hematol"},{"issue":"09","key":"ref40","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-016-2738-3","article-title":"Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children: splenectomy in ITP","volume":"95","author":"R Ahmed","year":"2016","journal-title":"Ann Hematol"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/ejh.12146","article-title":"Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia","volume":"91","author":"J R Gonzalez-Porras","year":"2013","journal-title":"Eur J Haematol"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2003-11-3908","article-title":"Long-term outcomes in adults with chronic ITP after splenectomy failure","volume":"104","author":"R McMillan","year":"2004","journal-title":"Blood"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"J N George","year":"1996","journal-title":"Blood"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4065\/79.4.504","article-title":"Management of immune thrombocytopenic purpura in adults","volume":"79","author":"R Stasi","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"R Stasi","year":"1995","journal-title":"Am J Med"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1767-0304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:22:55Z","timestamp":1682554975000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1767-0304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":45,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,4,26]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1767-0304","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}